A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: dalotuzumab (MK0646)
Sponsor: Merck Sharp & Dohme LLC